Promising research studies surrounding Retatrutide , specifically the 120 milligram formulation branded as ZPHC, suggest a considerable impact on body mass loss and linked chronic illnesses . Researchers believe that this combined compound, affecting both GLP-1 and GIP systems, could represent a